50th ASH Annual Meeting and Exposition (December 6

Sunday, December 7, 2008: 4:30 PM-6:00 PM

Yerba Buena Ballroom Salon 8 (San Francisco Marriott)

Moderators:

Veronika Bachanova and Paul Szabolcs, MD

4:30 PM

Identification of a Myeloid Pathway of NK Cell Development and a Myeloid-NK Cell Precursor

Bartosz Grzywacz, MD¹^*, Nandini Kataria, BS¹^*, Bruce R. Blazar, MD², Jeffrey S. Miller, MD² and Michael Verneris, MD²

¹Pediatrics, University of Minnesota, Minneapolis, MS
²University of Minnesota, Minneapolis, MN

4:45 PM

104

Invariant NKT Cells Regulate Osteoclast Development and Function Under Homeostatic and during Conditions of Immune Activation

Ming Hu¹^*, J.H. Duncan Basssett²^*, Lynette Danks³^*, Emmanouil Spanoudakis¹^*, Ke Xu¹^*, Peter GT Howell⁴^*, Alan Boyde⁴^*, Nikki Horwood³^*, Graham Williams¹^*, Irene AG Roberts¹ and Anastasios Karadimitris¹^*

¹Haematology, Imperial College London, London, United Kingdom
²Molecular Endocrinology Group, Division of Medicine and MRC Clinical Sciences Centre, Imperial College London, London, United Kingdom
³Kennedy Institute of Rheumatology, Imperial College London, London, United Kingdom
⁴Biophysics, Oral Growth and Development, Dental Institute, Queen Mary University of London, London, United Kingdom

5:00 PM

105

Antisense Transcripts Negatively Regulate Transcription of Multiple Variegated Killer Immunoglobulin-Like Receptor (KIR) Genes

Frank Cichocki¹^*, Todd Lenvik¹^*, Stephen K Anderson²^* and Jeffrey S. Miller, MD³

¹Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
²Basic Research Program, SAIC-Frederick, Frederick, MD
³University of Minnesota, Minneapolis, MN

5:15 PM

106

IL-18 Elicited Suppressor NK Cells with Immunoregulatory Functions

Evelyn Ullrich, MD¹^*, Magali Terme, PhD²^*, Laetitia Aymeric²^*, Lionel Apetoh, PhD²^*, Nathalie Chaput, PhD²^*, Bernhard Ryffel, PhD³^*, Andreas Mackensen, MD¹, Joachim L Schultze, MD⁴^* and Laurence Zitvogel, MD, PhD²^*

¹Department of Internal Medicine V, Hematology and Oncology, Erlangen, Germany
²Immunology INSERM U805, Institut Gustave Roussy, Villejuif, France
³Cnrs-Iem 2815, Institut Transgenose, Orleans, France
⁴Laboratory for Genomics and Immunoregulation, LIMES, Bonn, Germany

5:30 PM

107

Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Report

Janet Ayello, MS, MT¹, Stacey L Berg, MD²^*, Mark Krailo, PhD³^*, Carmella van de Ven, MS¹^*, Ashish Mark Ingle, MS³^*, Duane Lewis¹^*, Lauren Harrison, RN¹^*, Susan Blaney, MD²^*, Peter C. Adamson, MD⁴^* and Mitchell S. Cairo, MD⁵

¹Pediatrics, Columbia University Medical Center, New York, NY
²Pediatric Oncology, Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX
³Statistics, Children's Oncology Group - Operations Center, Arcadia, CA
⁴Office of Clinical and Translational Research, Childrens Hospital of Philadelphia, Philadelphia, PA
⁵Pediatrics, Medicine, and Pathology, Columbia University Medical Center, New York, NY

5:45 PM

108

Elotuzumab (HuLuc63) Activates CD56^dimNatural Killer Cells and Monocytes Resulting in the Release of IP-10 and MCP-1

Balaji Balasa, PhD¹^*, Mahrukh Huseni, MSc¹^*, Jyothi Cherukuri, MSc¹^*, Roxanne Steinle, BSc²^*, Amulya Nanisetti, MSc¹^*, Daniel Afar, PhD¹, Eric Hsi, MD² and Vladimir Vexler, PhD¹^*

¹PDL BioPharma Inc, Redwood City, CA
²Cleveland Clinic Foundation, Cleveland, OH

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

203.O1.6 NK Biology